The activity of the new fluoroquinolone gatifloxacin was compared with those of other quinolones and antimicrobial agents of other classes against 294 anaerobes by the broth microdilution technique. For all strains tested, gatifloxacin MICs at which 50 and 90% of the isolates were inhibited were 0.5 and 2 mg/liter, respectively, and were 3 to 4 dilution steps lower than, e.g., ciprofloxacin.
N 2 , 15% CO 2 , and 5% H 2 . Then, the bacteria were delivered by a semiautomated inoculator (MIC-2000; Dynatech Laboratories, Inc., Chantilly, Va.). The final inoculum was approximately 1.0 ϫ 10 5 CFU/well. Incubation was usually for 48 h (96 h for Bilophila wadsworthia) at 37°C in the anaerobic chamber. The MIC was defined as the lowest antibiotic concentration that inhibited visible growth.
Bacteroides fragilis ATCC 25285, B. fragilis ATCC 23745, Bacteroides ovatus ATCC 8483, Bacteroides vulgatus ATCC 8482, Bacteroides thetaiotaomicron ATCC 29148, Bacteroides caccae ATCC 43185, Fusobacterium mortiferum ATCC 9817, Fusobacterium varium ATCC 8501, and Peptostreptococcus magnus ATCC 14955 were used as reference strains. The MICs showed conformity with published results of the National Committee for Clinical Laboratory Standards and the German standard-setting organization Deutsches Institut für Normung (13, 15) . MIC distributions and MICs at which 50 or 90% of the isolates were inhibited (MIC 50 and MIC 90 , respectively) for gatifloxacin, other quinolones, and nonquinolone antimicrobials are given in Table 1 . In addition, in Table 2 the results are shown as cumulative percentages of strains inhibited at a given MIC. Overall, the MIC 50 and MIC 90 (in milligrams per liter), respectively, for all strains were as follows: imipenem, metronidazol, and trovafloxacin, 0.25 and 1; gatifloxacin, 0.5 and 2; clindamycin, 0.5 and 4; amoxicillin-clavulanate, 1 and 4; ciprofloxacin, 4 and 32; erythromycin, 4 and Ͼ32. At a breakpoint concentration of Յ1 mg of gatifloxacin per liter, 83% of all strains tested, 90% of the B. fragilis strains, and 81% of all Bacteroides spp. were inhibited. The MIC 50 and MIC 90 of gatifloxacin were 1 dilution step higher than those of trovafloxacin with respect to all strains tested. In contrast, gatifloxacin MIC 50 and MIC 90 were 3 to 4 dilution steps lower than those of ciprofloxacin. Gatifloxacin and trovafloxacin MICs were significantly lower for anaerobic gram-negative bacilli other than fusobacteria and Bilophila wadsworthia than MICs of ciprofloxacin. For Clostridium spp., no major disparities were found between gatifloxacin, trovafloxacin, and ciprofloxacin MIC 50 , whereas the MIC 90 for ciprofloxacin was 3 dilution steps higher than those of gatifloxacin and trovafloxacin.
In comparison with other studies (1, 5, 6, 12, 16-18, 22- Gatifloxacin  0  7  15  37  58  83  93  95  98  99  99  100  Ciprofloxacin  0  2  13  23  28  33  35  52  66  89  94  100  Trovafloxacin  2  12  35  60  81  95  99  100  Clindamycin  7  8  17  30  50  70  81  90  93  94  94  100  Metronidazole  7  13  28  54  87  100  100  Imipenem  2  21  42  68  89  99  100  100  Amoxicillin-Clavulanate  0  5  9  17  32  66  82  93  96  97  100  100  Erythromycin  0  0  1  2  8  30  45  63  79  87  88  100 (5, 7). The disparities might be due to technical differences, i.e., different media and our use of the broth microdilution technique rather than the agar dilution method. It is recognized that the results of in vitro anaerobe susceptibility testing do not always correlate with in vivo findings. Although Kato et al. described "mediocre" in vitro activity of gatifloxacin against B. fragilis, they reported that gatifloxacin was effective against both B. fragilis and Escherichia coli in a mixed infection in a rat granuloma pouch in vivo (11) . Hence, clinical studies are required to determine the roles of gatifloxacin in mixed and anaerobic infections.
